1-(4-Dimethylsulfamoyl-phenyl)-1,4,5,6-tetrahydro-benzo[1,2-c;3,4-c']dipyrazole-3-carboxylic acid ethyl ester | 586353-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-Dimethylsulfamoyl-phenyl)-1,4,5,6-tetrahydro-benzo[1,2-c;3,4-c']dipyrazole-3-carboxylic acid ethyl ester
• 英文别名: ethyl 1-[4-(dimethylsulfamoyl)phenyl]-5,6-dihydro-4H-pyrazolo[3,4-e]indazole-3-carboxylate
• CAS: 586353-09-5
• 化学式: C₁₉H₂₁N₅O₄S
• 分子量: 415.473
• InChiKey: VPINDKSUWNSLJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(4-Dimethylsulfamoyl-phenyl)-1,4,5,6-tetrahydro-benzo[1,2-c;3,4-c']dipyrazole-3-carboxylic acid ethyl ester 在 ammonium hydroxide 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.5h， 生成 1-(4-Dimethylsulfamoyl-phenyl)-1,6-dihydro-benzo[1,2-c;3,4-c']dipyrazole-3-carboxylic acid amide
  参考文献：
  名称：

  Benzodipyrazoles: a new class of potent CDK2 inhibitors

  摘要：

  The synthesis and the preliminary expansion of this new class of CDK2 inhibitors are presented. The synthesis was accomplished using a solution-phase protocol amenable to rapid parallel expansion and suitable to be scaled-up in view of possible lead development. Following a medicinal chemistry program aimed at improving cell permeability and selectivity, a series of compounds with nanomolar activity in the biochemical assay and able to efficiently inhibit tumor cell proliferation has been obtained.

  DOI：

  10.1016/j.bmcl.2005.01.023
• 作为产物：
  描述：

  4-Hydrazino-N,N'-dimethylbenzolsulfonamid 、 oxo-(4-oxo-2-trityl-4,5,6,7-tetrahydro-2H-indazol-5-yl)-acetic acid ethyl ester 在 溶剂黄146 作用下， 反应 3.0h， 生成 1-(4-Dimethylsulfamoyl-phenyl)-1,4,5,6-tetrahydro-benzo[1,2-c;3,4-c']dipyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Benzodipyrazoles: a new class of potent CDK2 inhibitors

  摘要：

  The synthesis and the preliminary expansion of this new class of CDK2 inhibitors are presented. The synthesis was accomplished using a solution-phase protocol amenable to rapid parallel expansion and suitable to be scaled-up in view of possible lead development. Following a medicinal chemistry program aimed at improving cell permeability and selectivity, a series of compounds with nanomolar activity in the biochemical assay and able to efficiently inhibit tumor cell proliferation has been obtained.

  DOI：

  10.1016/j.bmcl.2005.01.023

文献信息

• Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
  申请人：D'Alessio Roberto

  公开号：US20050176796A1

  公开（公告）日：2005-08-11

  Compounds which are tricyclic pyrazole derivatives and analogues thereof, as set forth in the specification, or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明揭示了三环吡唑衍生物及其类似物或药学上可接受的盐，以及包含它们的制药组合物；这些化合物或组合物在治疗由改变的蛋白激酶活性引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病。
• TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1478357A2

  公开（公告）日：2004-11-24
• [EN] TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE PYRAZOLE TRICYCLIQUE, PROCEDES DE LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'AGENTS ANTI-TUMORAUX
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2003070236A2

  公开（公告）日：2003-08-28

  Compounds which are tricyclic pyrazole derivatives and analogues thereof, as set forth in the specification, or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.